Targeted Nanomedicine for Treating Vascular Disorders
AssigneesThe University of Chicago, University of Utah
InventorsYun Fang, Matthew V. Tirrell, Yan-Ting Shiu
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compositions and methods for treating vascular disorders, including, for example, arteriovenous fistula (AVF) failure, stenosis, restenosis, and atherosclerosis.
Claims23
A method of treating a vascular disorder in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a targeted nanoparticle comprising an miR-92a inhibitor.
A method of treating a vascular disorder in a subject, comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a targeted nanoparticle comprising an miR-92a inhibitor, wherein the targeted nanoparticle is preferentially targeted to inflamed endothelial cells associated with the vascular disorder;
- and
- reducing inflammation at the site of the inflamed endothelial cells.
A method of promoting endothelial wound healing in a subject, comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a targeted nanoparticle comprising an miR-92a inhibitor, wherein the targeted nanoparticle is preferentially targeted to inflamed endothelial cells associated with the endothelial wound;
- and
- reducing inflammation at the site of the inflamed endothelial cells.
A method of treating a vascular disorder in a subject, comprising
- a) administering a therapeutically effective amount of a targeted nanoparticle to a patient, wherein the targeted nanoparticle comprises:
- an miR-92a inhibitor,
- and a PEG-containing peptide, comprising the sequence VHPKQHR-PEG-K30 (SEQ ID NO:
- 8);
- and
- b) treating the vascular disorder.
Dependencies are inferred from the claim text.